Propel the next generation of cancer therapeutics with novel multiomic insights from Guardant Infinity

The first and only platform that combines genomic, epigenomic,
and RNA-based fusion profiling to deliver multiomic insights

Novel, non-destructive
methylation technology enabling
far greater coverage and capture of
tumor signal across the methylome

A single technology platform
that powers our entire portfolio—building an expansive epigenomic
real-world database